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Although the origin of hepatitis C virus infections in hu-
mans remains undetermined, a close homolog of this virus, 
termed canine hepacivirus (CHV) and found in respiratory 
secretions of dogs, provides evidence for a wider distribu-
tion of hepaciviruses in mammals. We determined frequen-
cies of active infection among dogs and other mammals in 
the United Kingdom. Samples from dogs (46 respiratory, 99 
plasma, 45 autopsy samples) were CHV negative by PCR. 
Screening of 362 samples from cats, horses, donkeys, ro-
dents, and pigs identifi ed 3 (2%) positive samples from 142 
horses. These samples were genetically divergent from 
CHV and nonprimate hepaciviruses that horses were infect-
ed with during 2012 in New York state, USA. Investigation of 
infected horses demonstrated nonprimate hepacivirus per-
sistence, high viral loads in plasma (105–107 RNA copies/
mL), and liver function test results usually within reference 
ranges, although several values ranged from high normal 
to mildly elevated. Disease associations and host range of 
nonprimate hepaciviruses warrant further investigation.
Hepatitis C virus (HCV) is a positive-sense RNA vi-rus, classifi ed as the type member of the family Fla-
viviridae and the genus Hepacivirus. HCV is a major hu-
man pathogen, causing persistent infections that target and 
eventually destroy the liver in a substantial proportion of 
those infected (1,2). HCV infections are distributed world-
wide and have spread epidemically within the past 40–60 
years within western countries through blood-borne routes 
such as blood and blood product transfusion and injection 
drug use.
HCV shows considerable genetic diversity; 7 geno-
types show >30% nt sequence divergence from each other 
(3). Several of these genotypes are associated with sus-
pected endemic source areas in central and western sub-
Saharan Africa (genotypes 1, 2, and 4) (4–7) and Southeast 
Asia (genotypes 3 and 6) (8,9). These regions harbor the 
greatest diversity of HCV subtypes, implying a long-term, 
endemic circulation of the virus for several hundred years. 
The spread of certain genotype variants from these popula-
tions, such as 1a and 1b to Western countries, 3a among 
injection drug users in Europe, and 4a to Egypt, where it 
was extensively transmitted by medical injections (10–14), 
show several parallels with the emergence and rapid spread 
of HIV-1 among new risk groups from a central African 
reservoir over a similar time frame (15).
Based on this model, it has been frequently speculat-
ed that HCV could have an ultimate animal origin in >1 
nonhuman primate species, in much the same way as hu-
man HIV-1 originated from chimpanzees (15). Three of 
the Pan troglodytes chimpanzee subspecies are frequently 
infected in the wild with a lentivirus that ultimately was de-
rived from simian immunodefi ciency viruses infecting Old 
World monkey species (16). The hypothesis for an equiva-
lent nonhuman primate origin for HCV fueled several pub-
lished (17,18) and unpublished (S. Lyons et al., unpub. 
data) surveys for HCV or HCV-like viruses in chimpan-
zees, other apes, and a variety of Old World monkey spe-
cies (19). These studies were encouraged by the serendipi-
tous detection of a virus distantly related to HCV, termed 
GB virus B (GBV-B), in a laboratory-housed tamarin, a 
New World monkey (20,21). This detection was speculated 
to represent, in evolutionarily terms, the New World mon-
key homolog of HCV, a scenario that supports the possi-
bility for the widespread distribution of further HCV-like 
viruses among Old World monkey species in Africa and 
Asia. Despite the plausibility of this hypothesis, we found 
that no survey to date has detected or obtained serologic ev-
idence for infection with HCV or HCV-like viruses in any 
ape or Old World monkey species screened in published 
data (17,18) or in the aforementioned unpublished data of 
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Lyons et al. As a further puzzling observation, GBV-B in-
fection has not been reported in any other tamarin or other 
New World monkey species either in the wild or among 
captive animals. Like HCV, its origin remains unknown.
Considering this background and previous focus on pri-
mates for HCV origins, it came as a complete surprise that a 
virus, much more closely related to HCV than GBV-B, was 
recently described for domestic dogs (22). Its host and appar-
ent tropism for the respiratory tract (and potential association 
with infectious respiratory disease) represent major differ-
ences from what might be expected for a close relative of 
HCV. It came as a further surprise that CHV RNA sequenc-
es were detected in plasma samples from 8 of 103 horses 
in New York state, USA (23). Results of a novel serologic 
test of samples from horses for antibodies to the conserved 
nonstructural protein 3 (NS3) showed an overall seroposi-
tivity of 35%, and 80 samples from dogs were negative by 
serologic testing and PCR. The wider host range of the virus 
implied by these fi ndings led the authors to propose a new 
name, non-primate hepacivirus (NPHV) for CHV, and this 
new nomenclature is used in the current study.
To investigate the species distribution of NPHV or ho-
mologs in a range of mammalian species and to investigate 
clinical features of infection, we initiated large-scale PCR–
based screening of plasma, respiratory, and postmortem 
liver, spleen, and lung samples from horses, dogs, cats, and 
other species originating in the United Kingdom. The PCR 
was specifi c for conserved sequences in the 5′ untranslated 
region (5′-UTR) and the NS3 regions of NPHV. NPHV was 
detected in 3 horses (horse 1, horse 2, and horse 3); initial 
characterization of the epidemiology and clinical features 




A total of 552 samples were screened for the presence 
of NPHV RNA. Samples collected were from horses, dogs, 
cats, mice, pigs, and donkeys.  All horse, cat, and donkey 
samples were sourced from either excess diagnostic sam-
ples or previously archived study samples from the Royal 
(Dick) School of Veterinary Studies, University of Edin-
burgh, where the laboratory investigation for this study was 
performed. Buccal swab samples were obtained from dogs 
(Canis lupus familiaris) undergoing veterinary examina-
tion at the Edinburgh Dog and Cat home. Bronchoalveolar 
lavage samples were collected from dogs undergoing in-
vestigation of respiratory disease.
Venus blood samples were collected from 353 nonpri-
mates comprising 99 dogs, 158 horses and donkeys (142 
Equus ferus caballus, 16 Equus africanus asinus), 56 cats 
(Felis catus), 63 rodents (47 Apodemus sylvaticus, 8 Mus 
muscullus, 5 Myodes glareolus, 3 Microtus agrestis), and 
40 pigs (Sus scrofa). Plasma was separated by centrifu-
gation and frozen at −80°C until testing. Lung, liver, and 
spleen samples were obtained from dogs during autopsy 
at the pathology department of the school of veterinary 
studies and placed in RNAlater (QIAGEN, Crawley, UK) 
before RNA extraction. Samples of mouse liver were col-
lected from all rodents in East Lothian, Scotland except 2 
Mus muscullus for which liver samples were unavailable. 
All clinical sampling was undertaken with full owner 
consent and in line with Royal (Dick) School of Veterinary 
Studies institutional and UK ethical guidelines.
CHV and NPHV Screening
Screening for CHV and NPHV infections was per-
formed by using PCR; serologic screening for antibodies 
against CHV/NPHV was precluded by the non-availability 
of NS3 antigen used in a previous study (23). To validate 
the PCR, RNA transcripts were generated from a plasmid 
containing partial CHV NS3 cDNA by using the Ambion 
T7 transcription kit (Promega Corp., Southampton, UK). 
Transcripts were purifi ed with the RNeasy kit (QIAGEN), 
and concentrations were determined by using the Nano-
Drop 2000 (NanoDrop Products, Wilmington, DE, USA). 
RNA extractions were performed on 140 μL of plasma or 
respiratory sample by using the QIAmp viral extraction kit 
(QIAGEN) according to the manufacturer›s instructions 
and eluted in a fi nal volume of 60 μL. All tissue samples 
were homogenized in lysis buffer; RNA was extracted by 
using the RNeasy Mini Kit (QIAGEN) according to in-
structions and eluted in a fi nal volume of 60 μL. Periph-
eral blood mononuclear cells were separated from whole 
blood immediately after collection by centrifugation on a 
Ficoll-Hypaque density gradient by using Histopaque 1077 
according to manufacturer’s instructions (Sigma Aldrich, 
St. Louis, MO, USA), and RNA was extracted by using 
QIAmp RNA blood mini kit as instructed (QIAGEN) and 
eluted in fi nal volume of 100 μL.
RNA was converted to cDNA by using random hexam-
ers with the Reverse Transcription System A3500 (Prome-
ga) and then used in nested PCR with previously published 
CHV NS3 primers (22) Chv-0F1,Chv-0R1S1, Chv-0F2, 
and Chv-0R2 and new equine-based NS3 primers (Table 1) 
and amplifi ed by using 2 rounds of 30 cycles at 94°C for 
18 s, 50°C for 21 s, and 72°C for 1.5 min; and 1 cycle of 
72°C for 5 min, with 2 μL of fi rst-round amplicon added 
to the second round. Degenerate equine- and canine-based 
NS3 primers were designed on the basis of the sequence 
variability observed in the published NPHV sequences 
and used to additionally screen all samples from dogs and 
equids. The CHV NS3 transcript was tested by using both 
NS3 primer sets and used as a control in screening, with 
sensitivity of 0.5–5 RNA copies in a reaction (Tables 1,2).
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To confi rm positive results of screening, we designed 
degenerate primers derived from the NPHV sequences for 
the 5′-UTR and NS5B (Table 1). For all detected positive 
results, we used SuperScript III One-Step RT-PCR (Life 
Technologies, Paisley, UK) with 6 μL of RNA and cycling 
conditions as published (23) with 1 of the following fi rst-
round primer sets: EQ5→UTROS and EQ5→UTROAS 
or EQNS5BIS and EQNS5BIAS. From the fi rst round, 
2 uL was added to the second-round PCR with respec-
tive forward and reverse primer sets: EQ5→UTRIS and 
EQ5→UTRIAS or EQNSBIS2 and NS5BIAS2, with the 
following cycling conditions; 30 cycles at 94°C for 18 s, 
50°C for 21 s, and 72°C for 1.5 min; and 1 cycle of 72°C 
for 5 min.
Positive second-round PCR amplicons were sequenced 
in both directions by using the inner sense and inner anti-
sense primers used in the second round of amplifi cation. 
Sequencing was executed by using Big Dye Terminator 
version 3.1 (Applied Biosystems, Paisley, UK) according 
to the manufacturer’s instructions. Sequences were ana-
lyzed by using SSE version 1.0 software (24). Sequences 
obtained in this study have been assigned the GenBank ac-
cession nos. JX948116–JX948121.
Viral loads of positive samples were determined by 
real-time quantitative PCR and a standard calibration curve 
generated from a dilution series of the NS3 transcript. Di-
lutions were prepared from the CHV NS3 transcript from 
concentrations of 106 to 1 copy/μL; 5 μL of transcript 
RNA was used to generate cDNA by using random hex-
amers and reverse transcription. Five-microliter aliquots of 
cDNA were assayed in triplicate for the 3 positive samples 
in the same way. To quantify viral loads of positive sam-
ples, EQNS3IS and EQNS3IAS primers were used with 4 
μL of cDNA in the SensiFAST SYBR Hi-ROX Kit (Bio-
Line, London, UK) per manufacturer’s instructions (Table 
1) with the exception that the annealing temperature was 
reduced to 50°C and the extension time extended to 15 s. 
Samples were analyzed in triplicate and fl uorescence mea-
sured by using the Rotor-Gene Q system (QIAGEN). Vi-
ral loads were read from the standard curve generated and 
converted to RNA copies/mL for sample volume used in 
extraction and elution of the RNA.
Results
Sample Screening
To investigate the frequency of NPHV infection in 
dogs, 46 respiratory samples collected from dogs over a 
6-month period in the Edinburgh area were screened by pub-
lished PCR-based screening methods (22,23) by using prim-
ers from the 5′-UTR and NS3 regions. An RNA transcript 
from the NS3 region (23) verifi ed the sensitivity of the NS3-
based assay to single RNA copies per amplifi cation reaction 
(Table 2). All samples were negative in both genome regions 
(Table 3). Ninety-nine plasma samples from dogs that had a 
variety of clinical conditions and had been referred for virol-
ogy screening, along with 15 autopsy lung, liver, and spleen 
samples from dogs, were additionally screened; results were 
uniformly negative in both regions.
Since publication of the NS3- and 5′-UTR–based PCRs 
(22), comparative sequence data from several NPHV-in-
fected horses have become available (23). These data re-
vealed sequence variability in the primer binding regions 
of both primer sets. We therefore redesigned the screening 
primers in both regions (Table 1) to accommodate this. In 
the 5′-UTR region, it was additionally possible to ensure 
that primers matched homologous regions of HCV geno-
types 1–7. The new nested NS3 primers showed similar 
sensitivity for the NS3 transcript (Table 2). These new 
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Table 1. Transcript titration of nonprimate hepaciviruses with NS3 
primers in samples from domestic horses, United Kingdom 
Transcript RNA copies/mL Published NS3 New NS3 
5 x 106 2/2 2/2 
5 x 105 2/2 2/2 
5 x 104 2/2 2/2 
5,000 2/2 2/2 
500 2/2 2/2 
50 2/2 2/2 
5 2/2 2/2 
0.5 0/2 0/2 
0 0/2 0/2 
*NS, nonstructural protein. 
Table 2. Nonprimate hepaciviruses primer sequences for 5?UTR, NS3, and NS5B in samples from horses, United Kingdom* 
Primer Position Sequence, 5? ?3? 
EQ5?UTROS Forward outer sense ACA YYA CCA TGT GTC ACT CCC CCT 
EQ5?UTROAS Reverse outer antisense CYC ATG TCC TAT GGT CTA CGA GA 
EQ5?UTRIS Forward inner sense ACA CGG AAA YGG GTT AAC CAY ACY  C 
EQ5?UTRIAS Reverse inner antisense GCC CTC GCA AGC ATC CTA TCA G 
EQNS3OS Forward outer sense ATW TGT GAT GAR TGC CAY AGY AC 
EQNS3OAS Reverse outer antisense TAG TAG GTB ACA GCR TTA GCY CC 
EQNS3IS Forward inner sense TCY AAR GGT GTD AAG CTT GTT GT 
EQNS3IAS Reverse inner antisense TGG CAG AAG YTA AGR TGY CTY CC 
EQNS5BIS Forward outer sense AAR TGY TTT GAC TCY ACB GTC ACT C 
EQNS5BOIAS Reverse outer antisense ACT RTG ACT RAT YGT YTC CCA ACT CG 
EQNS5BIS2 Forward inner sense CAY GAT ATA GAH ACT GAG AGR GA 
EQNS5BIAS2 Reverse inner antisense TCR TCT TCC TCR ACG CCY TTR CTG G 
*UTR, untranslated region; NS, nonstructural protein.  
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primers were used to repeat screening of all canine respira-
tory, plasma, and autopsy samples that produced uniformly 
negative results (Table 3).
To investigate the possible infection of non-canine 
mammalian species, we screened available plasma/serum, 
respiratory, and liver samples from horses (n = 175), don-
keys (n = 16), domestic cats (n = 56), pigs (n = 40), and 
wild mice (n = 61) by using both sets of conserved primers 
(Table 3). From this extended survey, 3 plasma samples 
from horses were positive on initial screening and con-
fi rmed positive on reextraction and reamplifi cation in 5′-
UTR and NS3 regions. PCR of samples of all types from all 
other studied mammalian species showed negative results.
To confi rm the presence of NPHV sequences in the 3 
screen-positive horses, we further amplifi ed each sample 
using conserved primers in the NS5B region and compar-
ing amplifi ed sequences from each region with homologous 
regions of previously identifi ed positive horses (Figure). 
Although this method does not represent a comprehensive 
genetic analysis, these sequence comparisons demonstrat-
ed that each of the positive horses was infected with NPHV 
variants distinct from the transcript-positive control and 
from each of the 8 previously identifi ed infected horses in 
the USA. All 3 variants showed similar branching orders in 
each genome region, consistent with the observed lack of 
recombination in previous analyses (23).
Virologic and Clinical Examination 
of NPHV-positive Horses
 The 3 infected horses originated in Scotland and com-
prised 2 geldings and 1 mare, 12–20 years of age (Table 4). 
Clinical records of each horse from the time of sample 
collection failed to identify evidence of hepatitis or sys-
temic disease. Liver function tests provided no evidence 
for hepatic infl ammation: γ-glutamyl transferase (GGT) 
and glutamate dehydrogenase were within reference range, 
except a mildly elevated GGT level in horse 2 (Table 5). 
Testing also ruled out hepatic insuffi ciency: bile acid lev-
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Table 3.Nonprimate hepaciviruses sequences detected by using PCR on mammal samples, United Kingdom* 
Animal/sample type No. NS3 5?-UTR Published NS3 New primers, 5?-UTR 
Dog      
 Respiratory 53 0 0 0 0 
 Plasma 99 0 0 0 0 
 Lung 15 0 0 0 0 
 Liver 15 0 0 0 0 
 Spleen 15 0 0 0 0 
Horse      
 Respiratory 40 0 0 0 0 
 Plasma 142 3 3 3 3 
Donkey      
 Plasma 16 NA NA 0 0 
Cat      
 Plasma 56 NA NA 0 0 
Pig      
 Serum 40 NA NA 0 0 
Mouse      
 Liver 61 NA NA 0 0 
*Data from 23. NS, nonstructural protein; UTR, untranslated region; NA, not applicable. 
Figure. Phylogenetic analysis of A) 5′ untranslated region, B) nonstructural protein 3, and C) nonstructural protein 5B regions of nonprimate 
hepatitis virus sequence amplifi ed from screen-positive study animals. Neighbor-joining trees of nucleotide sequences from each genome 
region were constructed from Jukes-Cantor corrected pairwise distances calculated by using the program MEGA version 5 (25; datasets 
were bootstrap re-sampled 500× to indicate robustness of branching (values >70% shown on branches). The hepacivirus genotype 1a 
sequence, M62321, was used to root the tree (not shown). Scale bars indicate nucleotide substitutions per site.
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els were within reference range. Viral loads, measured by 
using real-time PCR against the NS3 transcript standard, 
ranged from 7 × 104 to 5 × 107 RNA copies/mL among the 
3 horses.
To clinically characterize NPHV infection, we further 
examined 1 of the positive horses (horse 3) and collected 
samples at 4 and 5 months after the original sample collec-
tion. The horse remained clinically unremarkable and had 
no specifi c signs indicative of systemic disease. The horse 
regularly competed in equestrian events and had traveled 
extensively worldwide during the 10 years preceding de-
tection of infection with NPHV. No specifi c risk factors, 
such as operations, exposure to unsterilized needles, or his-
tory of systemic illness were elicited by interviewing the 
owner. During the 5-month follow-up period, the horse re-
mained viremic, but samples showed lower viral loads (7 
× 104 to2 × 105 RNA copies/mL) than found in the initial 
sample (5 × 107 copies/mL) (Table 5). Although liver in-
dices were within the reference range, liver enzymes and 
bile acids were frequently at the upper end of the reference 
range. Although of questionable clinical signifi cance, these 
observations and the elevated GGT level in horse 2 are po-
tentially consistent with low-grade hepatitis. UK veterinary 
rules precluded taking a liver biopsy sample from horse 3 
to further investigate this.
Nasal and mouth swab samples and peripheral blood 
mononuclear cells collected at month 5 were NPHV nega-
tive by PCR when both sets of primers were tested. Screen-
ing plasma samples from 6 horses stabled with horse 3 were 
uniformly NPHV negative in 5′-UTR and NS3 by PCR.
Discussion
Although the study was designed as an investigation of 
the frequency of CHV infection in dogs, initial fi ndings of 
uniformly negative results from a large number of respira-
tory, plasma, and autopsy samples prompted us to widen 
our sampling to other mammalian species. Consistent with 
a then-recent report (23), we found viruses similar to CHV 
and now termed NPHV in »3% of horse plasma samples 
but in no samples from other species (cats, pigs, or mice), 
irrespective of sample type (Table 3). The detection fre-
quency in samples from horses 1, 2, and 3 was lower (but 
not signifi cantly so by the Fisher exact test; p = 0.06) than 
the previous 8 from 103 viremia frequency among horses 
in New York state (23).
The restriction of NPHV infection to horses was consis-
tent with serology-based screening (23) that showed 35% of 
samples from horses to contain antibodies against a recombi-
nant NPHV NS3 peptide (of which »25% were additionally 
viremic) but an absence of NS3 antibodies in other species. 
These included dogs, deer and rabbits, although 1 interme-
diately seroreactive (but NPHV-negative by PCR) sample 
was found in 84 samples screened from cows. Whether these 
fi ndings represent rare infection in another ruminant spe-
cies or assay non-specifi city requires further investigation. 
Although these initial surveys provide preliminary evidence 
that horses could be the natural host of NPHV, its previ-
ous detection in dogs with respiratory disease (22) provides 
evidence for its potential spread to humans. In this respect, 
NPHV specifi city would differ from the narrow specifi city 
observed in other hepaciviruses; e.g., HCV can infect hu-
mans and chimpanzees (although it does not naturally cir-
culate in the latter species) and cannot infect Old World 
monkey species, such as macaques (26). The host range of 
GBV-B appears similarly restricted to New World monkeys 
(27). Further studies are needed to determine whether ad-
ditional equally or more divergent hepaciviruses are distrib-
uted in other mammalian species; the 5′-UTR primers de-
veloped for the current study used with primers selective for 
regions conserved between NPHV and HCV might provide 
a useful assay for this purpose.
The detection of NPHV RNA sequences in samples 
obtained 5 months apart from horse 3 provides evidence 
for an ability of NPHV to establish persistent infections. 
Although longer term sampling is required to confi rm this 
possibility, the observation is consistent with the high vi-
remia frequencies among seropositive horses in a previous 
study (8/37) (23). This proportion would probably not be 
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Table 4. Clinical features of domestic horses infected by nonprimate hepaciviruses, United Kingdom* 
Horse Sample Collection date Area Age, y/sex Presenting disease 
1 EF_317/98 1998 Caithness 8/F Lameness 
2 EF_330/97 1997 Perthshire 12/M Inflammatory airway disease 
3 EF_369/11  2011 Dec 2 Lothian 20/M Lameness; no lung disease 
 EF_374/12 2012 Mar 1   Lameness; no lung disease 
 EF_523/12 2012 Mar 23   Lameness; no lung disease 
Table 5. Laboratory indices for domestic horses infected with nonprimate hepaciviruses, United Kingdom 
Horse Sample GGT (<40 U/mL) GLDH (<10 U/mL) Bile acids (<10 U/mL) Viral load, copies/mL 
1 EF_317/98 15 2 1 1.3 × 105
2 EF_330/97 59 2 3 4.4 × 105
3 EF_369/11 15 2 6.4 4.8 × 107
EF_374/12 36 1 7.4 2.1 × 105
EF_523/12 24 4 6.3 7.1 × 104
*GGT, ?-glutamyl transferase; GLDH, glutamate dehydrogenase. 
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observed on random sampling if infections had rapidly re-
solved. In this respect, NPHV may at least partly repro-
duce the documented high rates of HCV persistence, in 
which >50% of those exposed showed decades- or life-
long viremia and active liver disease in the absence of 
treatment. GBV-B, although clearly hepatotropic, does not 
establish persistent infections in tamarins or owl monkeys 
(20,27,28). However, more recent studies have demonstrat-
ed long-term persistence among experimentally infected 
marmosets (29,30).
Neither the clinical signs nor the liver function tests of 
the 3 NPHV-infected horses provided a clear indication of 
the organism’s association with hepatic or other systemic 
disease (Tables 4, 5). GGT and glutamate dehydrogenase 
are sensitive markers of liver infl ammatory processes in the 
horse but with 1 exception were in the reference range. Ref-
erence levels of bile acids similarly demonstrated adequate 
liver function. Although the sample size was small, these 
relatively normal liver indices contrast with the frequent 
GGT and ALT elevations associated with chronic HCV in-
fection and found in New World monkeys experimentally 
infected with GBV-B. Although in the current study, UK 
veterinary regulations did not permit liver biopsies to be 
performed on horses without evidence of liver disease, the 
current fi ndings do not rule out a lower grade infection or 
potential replication in the liver without the associated im-
munologic response to HCV that is primarily responsible 
for liver damage (31,32). Future studies, perhaps refocused 
on NPHV screening of horses with idiopathic liver dis-
ease that have undergone biopsy sampling and have been 
clinically characterized, are needed to investigate further 
the potential for hepatotropic NPHV and manifest its clini-
cal effects. In the longer term, and acknowledging that the 
horse is not the ideal experimental animal, inoculation of 
horses with NPHV and subsequent monitoring for viremia 
development, liver function abnormalities, and B- and T-
cell immune responses would provide further insights into 
the nature of NPHV infections and associated immune re-
sponse and similarity of these developments to current ob-
servations for HCV and GBV-B.
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